Chongqing re creates 2.2 billion new class I drugs to realize technology transfer abroad

Yesterday, Chongqing Science and Technology Commission introduced that the transfer created two firsts, which is the first time for Chongqing pharmaceutical enterprises to realize the transfer of foreign technology for their own R & D projects, which is the highest price so far for Chinese enterprises to sell their own R & D projects These two projects are independently developed by Chongqing fuchuang Pharmaceutical Research Co., Ltd This is a new drug R & D company jointly owned by Chongqing pharmaceutical industry Research Institute Co., Ltd and Shanghai Fosun Pharmaceutical Co., Ltd and the only pharmaceutical enterprise in Chongqing engaged in the research and development of chemical small molecule innovative drugs Zeng fanxin, biological director of fuchuang Pharmaceutical Research Co., Ltd., introduced that "after the company was registered and established in March 2009, it started the development of chemical 1.1 new drugs." Fugletin benzoate, a new antidiabetic drug developed by the company, can treat diabetes by inhibiting DPP-IV to increase the GLP-I of glucagon like peptide in human body, thus promoting the secretion of insulin Zeng fanxin introduced that the new drug is an oral drug, which has more significant curative effect compared with other similar drugs; it has less side effects, will not cause hypoglycemia and weight gain; it can protect the β cells that secrete insulin in the body, and can delay and prevent the development of diabetes Pan her, a new antitumor drug, is aimed at lung cancer It has an effect on many cancer factors in her family, which is the target of cancer By inhibiting them, we can achieve the purpose of antitumor "In the past, anticancer drugs were often treated in the second and third line after conventional chemotherapy Our new drugs may be the first-line treatment for some lung cancer categories in the future." Zeng fanxin introduced that the drug has high selectivity for cancer cells, can automatically identify which ones are cancer cells, carry out targeted "killing", and the treatment effect is good The side effect is smaller If a patient has resistance to the first generation of similar drugs, the drug is still effective In the Sino EU science and technology exchange event hosted by the Ministry of science and technology at the end of August this year, the Hellenic sellas head office came to Chongqing for investigation after learning the news of the two new drugs An agreement was signed on October 23 to purchase the overseas market rights of the two new drugs for 3.2 billion yuan The transfer agreement signed by fuchuang and sellas will pay the transfer fee in installments, with an initial payment of 8 million euros, and the rest will be paid according to the progress of the drug test In the future, Fu Chuang company will also get 10% of the net sales commission Sellas is a Greek company registered in Switzerland, mainly engaged in clinical research cro, diagnostic reagent sales, hospital acquisition and management, drug and medical device research and development Lei Huangshu, senior assistant to the general manager of Chongqing pharmaceutical industry research Co., Ltd., said that the principle of the company's purchase is: first, to be original, that is, to have independent intellectual property rights; second, to be more effective, safe and economic than the existing drugs, which can bring high profits to the enterprise These two new drugs in Chongqing meet these two requirements Fugletin benzoate has obtained the clinical approval document in September this year and will enter the phase I clinical trial immediately It is expected that the completion time of phase III clinical trials will be 3-5 years, and the drugs will be available for sale at that time According to Lei Huangshu, the domestic market right of fugletin benzoate has also been successfully transferred to a pharmaceutical enterprise in Shenzhen, with a technology transfer fee of 25 million yuan At the same time, many domestic pharmaceutical enterprises have shown great interest in the domestic market right of Pan her inhibitor, which is under negotiation Efficacy: antidiabetic advantages: compared with other similar drugs, it has more significant curative effect, less side effects, and will not cause hypoglycemia and weight gain Efficacy: anti tumor advantages: after the discovery of cancer, it can be taken for treatment, can automatically identify cancer cells, with good effect and low side effect and drug resistance The development of innovative drugs is characterized by huge investment, long cycle and high risk Generally, it takes 10 years to develop a drug However, fuchuang Pharmaceutical Research Co., Ltd., established in 2009, has developed 10 new chemical 1.1 drug projects Two projects have realized the transfer of domestic rights and interests, two projects have realized the transfer of foreign rights and applied for 10 PCT patents Why are there such high R & D efficiency and achievements? Zeng fanxin said that Dr Wang Weibo, founder and President of the company, was the main reason for the establishment of fuchuang After graduating from Shanghai Institute of organic chemistry, Chinese Academy of Sciences, Wang Weibo, 48, went to Northwestern University to engage in postdoctoral research, and then worked as a senior researcher and project leader in Abbott Laboratories Later, he joined Chiron Corporation as the deputy director of drug discovery department In 2006, geo pharmaceutical company was founded in the United States He was awarded the first prize of science and technology innovation by the Chinese Academy of Sciences in 1991, the second prize of National Natural Science in 1993, the president mentor prize of Abbott in 1997, the Sixth Batch of "thousand talents plan" in 2011 and the "hundred talents plan" of Chongqing in 2012 In 2009, Wang Weibo returned to China to start his own business Among the more than 50 new drug R & D teams composed by fuchuang and the Medical Engineering Institute, there are 1 national "thousand talents plan" expert, 2 Chongqing "hundred talents plan" experts, more than 10 professor level senior engineers, more than 10 overseas returned doctors and more than 20 masters "Our company is very unique in the layout of the two countries and three places." Zeng fanxin said that the company is headquartered in the northern New Area, and has established two wholly-owned subsidiaries in Zhangjiang, Shanghai and San Francisco, USA, with R & D personnel in all three places Zeng fanxin introduced that the US subsidiary is mainly responsible for the collection of new drug information and the design of new compounds Chongqing head office is mainly responsible for the rapid synthesis and screening of new compounds designed, and Shanghai subsidiary is mainly responsible for the entrusted outsourcing management of the project The "two countries and three regions" operate together By taking advantage of the time difference between China and the United States, the laboratories on both sides can operate 24 hours without interruption, and the R & D efficiency has doubled The research done by other companies in two years can be completed in one year In addition, the rapid promotion of the project of fuchuang company can not be separated from the strong support of its brother, Chongqing Medical Engineering Institute After the project enters the preclinical research stage, fuchuang cooperates closely with the medical engineering institute to fully share the existing R & D resources and platforms of Chongqing Medical Engineering Institute, so that the whole project can be promoted quickly and efficiently.